Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single Injection, Three Injection, Five Injection), By End-User (Hospitals, Orthopaedic Clinics/Ambulatory Surgical Centers (ASCs)) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Viscosupplementation Market Size

The global viscosupplementation market size was valued at USD 5.86 billion in 2025 and is projected to grow from USD 6.39 billion in 2026 to USD 12.69 billion by 2034, registering a CAGR of 8.96% during the forecast period from 2026 to 2034. Asia Pacific dominated the viscosupplementation market with a market share of 36% in 2025.

Patients with hip, knee, ankle, or spine osteoarthritis may benefit from the medical therapy known as viscosupplementation. Other kinds of joint discomfort can also be treated with the procedure. In most cases, providing a numbing injection into the area around the knee joint constitutes the first course of treatment. Any extra fluid will be removed in this way, preventing the swelling of the joint. After some time, the region inside the joint will receive an injection of hyaluronic acid. As a result, the synovial fluid that typically lubricates the joint gradually loses some of its effectiveness. The fluid softens the joints while also acting as lubrication to lessen friction in the system. It has the viscosity of a thick gel. The liquid's thick gel-like consistency is why it has this effect.

Osteoarthritis patients have much lower levels of hyaluronic acid in their joints than healthy individuals. They experience stiffness, edema, and discomfort, which all add to their misery. Even after a hyaluronic acid injection into a joint, the patient could have discomfort after the procedure. Once patients have finished the specified course of medication, they may experience reduced discomfort.

Product Analysis

The global market for viscosupplementation is bifurcated into single injection, three injections, and five injections.

The three-injection segment dominates the global market and is projected to exhibit a CAGR of 8.55% over the forecast period. Since the beginning of the 2000s, several injections have become commercially available, and as a direct result, they have successfully cornered a substantial portion of the market for viscosupplementation. After the first injection, a second dose will be planned based on the findings, and within six months following the first injection, it will be put up for review and approval. In patients suffering from knee osteoarthritis, medical professionals will frequently propose the administration of three injections as a feasible alternative to knee replacement surgery. It is anticipated that an increase in the number of FDA approvals for three-injection viscosupplements will benefit the market's growth. This is because there is a growing demand for these products.

Request Customizationto receive a tailored report.

End-User Analysis

The global market is divided into hospitals, orthopedic clinics/ambulatory surgical centers (ASCs).

The orthopedic clinics/ambulatory surgical centers (ASCs) segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 9.95% over the forecast period. Ambulatory Surgical Centers, or ASCs, are outpatient surgery centers primarily providing surgical care on the same day. This can include both diagnostic and preventative (surgical) procedures. Various procedures, including knee replacement, ACL surgery, hip replacement, shoulder replacement, and others, can be performed on the same day at ASCs. These procedures are less involved and need shorter time, if any, in the hospital. In addition, treating issues relating to the musculoskeletal system is the primary focus of orthopedic clinics. This involves the surgical and non-surgical treatment of issues involving the joints, bones, ligaments, muscles, and nerves in the spine and other body areas. One of the primary aspects anticipated to contribute significantly to expanding this market segment is the rising incidence of osteoarthritis in older people.

Speak to an Analystto discuss market opportunities.

Regional Insights

Based on region, the global Viscosupplementation Market share is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Asia-Pacific Dominates the Global Market

Asia-Pacific is the most significant global Viscosupplementation Market shareholder and is estimated to exhibit a CAGR of 9.48% over the forecast period. The rapid economic expansion that has been observed in developing nations like China, Japan, and South Korea, as well as India, has resulted in the upgrading of medical facilities in these countries, which has resulted in the Asia Pacific area being anticipated as the market with the most potential to be profitable. In contrast to its cousin, the multiple-injection therapy cycle has shown better demand in Asia. This can be explained by the fact that it has more than one injection every treatment cycle. This is because people in this region have a larger need for goods that are available at lower prices.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe: Fastest-Growing Region

Europe is anticipated to exhibit a CAGR of 10.39% over the forecast period. The region's market development slowed slightly due to ongoing economic turmoil and intensifying market competition. With the introduction of single-injection remedies, the market is anticipated to recover. The European market for viscosupplements is anticipated to experience a significant transition from multiple-injection cycle products to single-injection treatments due to the latter's greater convenience. Due to the greater relative cost-benefit offered by single-injection treatments over the forecast period, the three-injection treatment segment is also anticipated to lose a portion of its market share to single-injection treatments.

Furthermore, numerous regional organizations are working to reduce the prevalence of osteoarthritis and osteoporosis. The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) provides efficient practitioners with the most recent economic and clinical information and serves as a forum for interaction among clinical scientists concerned with bone and muscle disorders, the pharmaceutical industry developing newer compounds in this field, responsible regulators for the registration of such drugs, health policymakers, and others.

In North American market, expanding preference for shorter treatment regimens, despite high prices, and expanding prevalence of target conditions, such as osteoarthritis, are high-impact rendering drivers that may be attributed to the substantial portion of this share. In recent years, the application of hyaluronic acid in the form of viscosupplements for managing osteoarthritis in the North American region has been the most lucrative. It is projected that the single-injection cycle would display the most constant increase since, compared to its three-injection and five-injection counterparts, it provides greater convenience. In the coming years, the growing demand for shorter treatment cycles among the public may be the primary factor that drives the expansion of single-injection cycles.

Latin America is seen as a potential market for viscosupplements due to the improvement made to the region's healthcare system and the growing average income per person in the region. The cycle of only one injection per day is becoming increasingly common in this region of the world. Individuals in Latin America focus more on reimbursement and pricing when choosing a hyaluronic acid therapy than on efficacy and safety ratings, which are considered in other parts of the world. This is in contrast to individuals in other parts of the world. There has been an increase in the number of individuals looking for pain treatment through viscosupplements due to the growing tendency among medical practitioners to postpone knee replacement surgery for as long as it is practically possible. Establishing local distribution networks is one strategy that many companies utilize to penetrate this area's market.

In the Middle East and Africa, westernization has led to an increased prevalence of obesity, which eventually can be attributed to the rising number of osteoarthritis patients in the region. Rising concerns over the scenario of musculoskeletal disorders in the region may increase the demand for viscosupplements. For instance, a division of the Emirati Medical Association (EMA) and the Emirates Osteoporosis Society (EOS) in association have contacted the government to raise awareness about osteoporosis treatment and prevention. Moreover, increasing reimbursement policies in the region may further drive the market for viscosupplementation in this region. For instance, the treatment of osteoporosis and DXA exams are reimbursed for UAE nationals. Although viscosupplements have not been well-penetrated in the region, the market is expected to grow steadily over the forecast period. MONOVISC and ORTHOVISC are available in certain countries in the Middle East.

List of Key and Emerging Players in Viscosupplementation Market